Press Release: Dupixent® (dupilumab) sBLA for treatment of eosinophilic esophagitis in children aged 1 to 11 accepted for FDA Priority Review

https://ift.tt/CaX3Wey

 

from Sanofi - Aventis Groupe https://ift.tt/GFrXNxS
via IFTTT